Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2C | Q14957 | 6/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627023 | 0.90 | GRIN2C (0.59) | GRIN2CTP53MTNR1BLMNAMAPT | |
| SCHEMBL5102988 | 0.86 | GRIN2C (0.59) | GRIN2CTP53MTNR1BCYP3A4CYP2D6 | |
| SCHEMBL5105385 | 0.83 | GRIN2C (0.61) | GRIN2C | |
| SCHEMBL16627050 | 0.82 | MTNR1B (0.60) | MTNR1BLMNAMAPTNPSR1CYP3A4 | |
| SCHEMBL5116464 | 0.81 | GRIN2C (0.60) | GRIN2CTP53 | |
| SCHEMBL5105177 | 0.80 | GRIN2C (0.58) | GRIN2CTP53CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL16627022 | 0.80 | GAA (0.56) | TP53MTNR1BLMNAMAPTNPSR1 | |
| SCHEMBL16625797 | 0.80 | GRIN2C (0.50) | GRIN2CTP53MTNR1BLMNAMAPT | |
| SCHEMBL7902332 | 0.80 | GRIN2C (0.81) | GRIN2C | |
| SCHEMBL9587165 | 0.79 | DRD2 (0.66) | GRIN2CTP53MTNR1BLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| WO-2015051106-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | MALLINCKRODT LLC (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | GRIN2C 1317/4885TP53 527/4885MTNR1B 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.